PEN Penumbra Inc NYSE · United States

Penumbra (PEN) news

Penumbra Inc is a public biotech or pharmaceutical company listed on NYSE under the ticker PEN, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Penumbra news

We have not published a story on Penumbra yet. When there is news, it will appear here.

Penumbra annual financials

Line	FY2025	FY2024
Revenue	$1.40 billion	$1.19 billion
Net income (loss)	$177.7 million	$14.0 million
Cash from operations	$238.7 million	$168.5 million
Cash and equivalents	$186.9 million	$324.4 million
Short-term investments	$357.9 million	$15.7 million

Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $254.3 million, plus short-term investments of $419.3 million, $673.6 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Penumbra

What is the ticker symbol of Penumbra?

Penumbra Inc trades under the ticker PEN on NYSE.

Where is Penumbra listed?

Penumbra Inc is listed on NYSE.

Which country or territory is Penumbra listed under?

Our directory records Penumbra Inc under United States.

Does aibio.space cover Penumbra?

aibio.space lists Penumbra Inc among 2,820 public biotech companies and publishes its news here as stories appear.

What was Penumbra's revenue last year?

$1.40 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Penumbra profitable?

Penumbra Inc reported net income of $177.7 million for the fiscal year ended Dec 31, 2025, and generated $238.7 million of cash from operations, per its annual report to the SEC.

How much cash does Penumbra have?

$673.6 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.

Investor discussion: Penumbra

Members talk about Penumbra (PEN). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Penumbra, newest first. Each line links the filing it comes from.

May 7, 2026Mergers
Filed documents for a merger or acquisition. SEC Form 425. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NYSE:PEN on TradingView.

Listing details

Company: Penumbra Inc
Ticker: PEN
Listing: NYSE
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction